MiroBio, a company founded by scientists from the University of Oxford, has developed a groundbreaking platform that leverages natural signaling mechanisms to create antibodies. These antibodies activate inhibitory pathways and restore immune balance, offering potential benefits to patients with autoimmune diseases. With a mission to deliver transformative immunotherapies, MiroBio's precise activation technology aims to provide durable remission for chronic conditions. Backed by a decade of foundational research and a team of experts, MiroBio is at the forefront of this emerging field of immunology.